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Abstract
Background: Glioblastomas (GBM), the most frequent malignant brain tumors in adults, are characterized by an
aggressive local growth pattern and highly invasive tumor cells. This invasion is facilitated by expression of matrix
metalloproteinases (MMPs), a family of zinc-dependent endopeptidases. They mediate the degradation of protein
components of the extracellular matrix. Twenty-three family members are known. Elevated levels of several of them
have been reported in GBM. GBM cell-lines are used for in vitro studies of cell migration and invasion. Therefore, it
is essential to know their MMP expression patterns. Only limited data for some of the cell-lines are published, yet.
To fill the gaps in our knowledge would help to choose suitable model systems for analysis of regulation and
function of MMPs during GBM tumorigenesis, cell migration and invasion.
Findings: We analysed MMP-1, -8, -9, -10, -11, -13, -17, -19, -20, -21, -23, -24, -26, -27, and MMP-28 expression in
seven GBM cell-lines (SNB-19, GaMG, U251, U87, U373, U343, U138) and in four primary cell cultures by
semiquantitative RT-PCR, followed changes in the MMP expression pattern with increasing passages of cell culture
and examined the influence of TNF-a and TGF-b1 stimulation on the expression of selected MMPs in U251 and
U373 cells.
MMP-13, -17, -19 and -24 were expressed by all analyzed cell-lines, whereas MMP-20 and MMP-21 were not
expressed by any of them. The other MMPs showed variable expression, which was dependent on passage num-
ber. Primary cells displayed a similar MMP-expression pattern as the cell-lines. In U251 and U373 cells expression of
MMP-9 and MMP-19 was stimulated by TNF-a. MMP-1 mRNA expression was significantly increased in U373 cells,
but not in U251 cells by this cytokine. Whereas TGF-b1 had no impact on MMP expression in U251 cells, it signifi-
cantly induced MMP-11 and MMP-24 expression in U373 cells.
Conclusions: Literature-data and our own results suggest that the expression pattern of MMPs is highly variable,
dependent on the cell-line and the cell-culture conditions used and that also regulation of MMP expression by
cytokines is cell-line dependent. This is of high impact for the transfer of cell-culture experiments to clinical
implementation.
Findings
Background
Glioblastomas (GBM) are the most common malignant
brain tumors in adults [1]. Patients have very limited
prognosis due to the aggressive local growth pattern of
these tumors [2-4]. Invasion of tumor cells into the
healthy brain tissue is facilitated by expression of differ-
ent proteolytic enzymes like matrix metalloproteinases
(MMPs), a family of zinc-dependent endopeptidases
[5,6]. They mediate the degradation of protein compo-
nents of the extracellular matrix [7]. To date, 23 mem-
bers of the human MMP gene family are known [8].
Elevated levels of several MMPs, like for example
MMP-1, -2, -7, -9, -11, -12, -14, -15, -19, -24 and -25
have been reported in malignant glioma samples from
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patients [6,9-20], suggesting that their expression is clo-
sely related to malignant progression in vivo.
Human GBM cell-lines are used for in vitro studies of
cell migration and invasion [21-24] and numerous stu-
dies investigated expression of selected MMPs in human
GBM cell-lines (Table 1) [10,15,19,20,25-36]. However,
several MMPs have not been analysed in these cells, yet.
Therefore, there are large gaps in our knowledge about
MMP expression in human GBM cell-lines. To fill these
gaps would help to choose suitable model systems for
the analysis of regulation and function of MMPs during
GBM tumorigenesis, cell migration and invasion.
In seven glioblastoma cell-lines (SNB-19, GaMG,
U251, U87, U373, U343, U138) and in four primary cell
cultures, established from tumor specimens analysed
previously by our group [16], we performed a compre-
hensive study of MMP expression using semiquantitative
RT-PCR. In addition, we followed changes in the MMP
expression pattern with increasing passages of cell cul-
ture and we examined the influence of TNF-a and
TGF-b1 stimulation on the expression of selected
MMPs in U251 and U373 cells.
Expression of MMPs in glioblastoma cell-lines
Expression of fifteen MMPs was analysed in the seven
GBM cell-lines SNB-19, GaMG, U251, U87, U373, U343
and U138 by semiquantitative RT-PCR (Figure 1).
Those MMPs were examined with no or very limited
data published about their expression in GBM cell-lines.
No mRNA expression was detectable for MMP-8, -20,
-21, -26 and MMP-27 (Figure 1). MMP-19 mRNA was
strongly expressed in all analysed cell-lines, whereas
MMP-10, -17 and -23 mRNAs were only very weakly
detectable (Figure 1). The other surveyed MMPs showed
a diverse expression in the different GBM cell-lines
(Figure 1).
These results became more obvious after densitometric
quantification (Figure 2). MMP-19 was highly expressed in
U87, U343 and U138 cells (Figure 1, Figure 2). Whereas
its expression remained stable for 15 passages in SNB-19,
U373, U343 and U138 cells, there was a statistically signifi-
cant decrease of MMP-19 mRNA expression at passage 15
in GaMG, U251 and U87 cells (Figure 2). MMP-1 mRNA
expression was strongest in U87, U343 and U138 cells and
remained stable for 15 passages. However, it was very
weakly expressed in SNB-19 and U373 cells and the inter-
mediate expression in GaMG and U251 cells was
successively reduced with passaging of cells (Figure 2).
A comparable reduction of mRNA expression was found
for MMP-11 in GaMG and U251 cells, MMP-17 in
GaMG cells and MMP-24 in SNB-19, GaMG, U251 and
U87 cells (Figure 2). MMP-10 was not detectable in U87
cells, MMP-11 not in SNB-19, U87 and U373 cells,
Table 1 MMP expression in glioblastoma cell-lines
SNB-19 GaMG U251 U87 U373 U343 U138
MMP-1 + + +25,31,35 +/-15,28,35 +35 +25 +
MMP-2 +19,20 +19 +19,20,25,26,31,35,36/-33 +10,15,28,33,35,36 +10,19,35,36 -25 +19,36
MMP-3 +19 -19 +19,31,6 +15,36/-28 +36/-19 +19/-36
MMP-7 +19 -19 +19,26,31,35,36 +15,30/-35 +19,35,36 +636/-19
MMP-8 - - +31/-26 - - - -
MMP-9 +29,30/-19 +19 +19,31/-25,36 +10,15,36/-28 +10,19/-36 -25 -19,36
MMP-10 + + +26,31 - + + +
MMP-11 - + +31/-35 -35 +35/- + +
MMP-12 +19 -19 +19,31/-36 +36 -19,36 +19/-36
MMP-13 + + +26,31 + + + +
MMP-14 +20 +20,26,31,34-36 +10,15,31,32,35,36/-28 +31,35,36/-10 +31 +36
MMP-15 +31,34,35 +31,32/-35 +31/-35 +31
MMP-16 +26,34/-31,35 +31,32,35 -31,35 -31
MMP-17 + + +31 +31 +31 +31 +
MMP-19 + + +31 + + + +
MMP-20 - - -31 - - - -
MMP-21 - - -31 - - - -
MMP-23 + - +31 + + + +
MMP-24 + + +31,34 +31 +31 +31 +
MMP-25 -31 -31 -31 -31
MMP-26 - - +31/-27 - - - -
MMP-27 - - +31/- - - - -
MMP-28 + - +31 - + + -
+: expressed; -: not expressed; bolt: data from this study; Figures: References.
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MMP-23 not in GaMG cells and MMP-28 not in U87
cells (Figure 2). An increase of MMP expression was visi-
ble at passage 5 in U373 cells for MMP-9 and in GaMG
cells for MMP-11, MMP-19 and MMP-24 (Figure 2). This
increase was reduced again with further duration of cul-
ture (Figure 2). The other MMPs were expressed in vary-
ing amounts in the different cell-lines and their expression
remained stable over the passages tested (Figure 2).
Expression of MMPs in primary glioblastoma cells
In addition to the cell-lines, four primary GBM cell
cutures, which were derived from patient’s tumor sam-
ples [16], were analysed for MMP-1, -8, -9, -10, -11, -13,
-17, -19, -23, -24 and MMP-28 mRNA expression by
semiquantitative RT-PCR (Figure 3). Very faint expres-
sion was detectable for MMP-8, -10, -13 and MMP-28
(Figure 3). Strongest expression could be found for
MMP-1, -11 and MMP-19 in the four primary cells
(Figure 3). MMP-17, -23 and MMP-24 showed inter-
mediate expression (Figure 3). MMP-9 was strongly
expressed in passage 1 of the primary cells, but its
expression successively decreased and almost disap-
peared at passage 10 (Figure 3). Similar data were
obtained for MMP-1, MMP-17 and MMP-24, with
exception that the latter was expressed constantly in
2262 cells for the investigated 10 passages (Figure 3).
Whereas MMP-23 expression remained unchanged in
the primary cells 2262, 2487 and 2369, its expression
was reduced with duration of cell culture in 2423 cells
(Figure 3). 2423 cells also were distinctive in MMP-11
expression, since it was increased with advancing pas-
sages (Figure 3).
Stimulation of MMP expression by TNF-a and TGF-b1 in
U251 and U373 cells
The data presented above indicate that there is a large
variety in the MMP expression patterns between different
cell-lines and primary cells and that these expression pat-
terns even change with the duration of cell culture.
Therefore, we tested whether GBM cell-lines also may be
Figure 1 Expression analysis of MMPs in glioblastoma cell-lines and primary cells by semiquantitative RT-PCR. Total RNA from the seven
glioblastoma cell-lines SNB-19, GaMG, U251, U87, U373, U343 and U138 was used as template for semiquantitative RT-PCR analysis. Cells were
passaged fifteen times and samples of total RNA were isolated from passage 0 (p0), passage 5 (p5) and passage 15 (p15). Primers were designed
in flanking exons specific for each transcript (Table 2). The length of the cDNA amplicons in base pairs (bp) is shown on the right side of the
figure. As positive control (+) genomic DNA from GaMG cells was used, except for MMP-10 and MMP-24 where cDNA of HBMEK cells and for
GAPDH where cDNA from U87 cells served as positive control. The various cDNA concentrations were normalized to that of the housekeeping
gene GAPDH, which was used as internal loading control. Shown is one representative experiment out of six.
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Figure 2 Densitometric quantification of MMP mRNA expression in glioblastoma cell-lines. Comparison of densitometrically quantified
MMP mRNA expression by human GBM cell-lines SNB19, GaMG, U251, U87, U373, U343 and U138 in arbitrary units. Each value was normalized
to the respective GAPDH mRNA expression. Shown are the means of six independent experiments. The standard errors of the mean (SE) are
shown as error-bars. Asterisks indicate statistically significant alterations in expression compared to the expression in passage p0, triangles in
comparison to the expression in passage p5 (two-tailed t-test, p ≤ 0.05). White columns: passage p0, light grey columns: passage p5, dark grey
columns: passage p15.
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different in their ability to regulate MMP expression after
stimulation with cytokines like TNF-a or TGF-b1. U251
and U373 GBM cells were successively adjusted to grow
in medium without FCS to avoid artefacts by starvation
shock and then stimulated either with TNF-a (10 ng/ml)
or TGF-b1 (10 ng/ml). Expression of MMP-1, -9, -11,
-19 and MMP-24 was determined by semiquantitative
RT-PCR (Figure 4). In both cell-lines TNF-a stimulated
expression of MMP-9 and MMP-19 (Figure 4). MMP-1
mRNA expression was significantly increased in U373
cells by TNF-a stimulation, whereas MMP-1 expression
in U251 cells remained unaffected (Figure 4). TGF-b1
had no impact on MMP expression in U251 cells. How-
ever, in U373 cells MMP-11 and MMP-24 expression
was significantly increased (Figure 4).
Together these data suggest that not only is the
expression pattern of MMPs different in the analysed
GBM cell-lines and primary cells, but that also regula-
tion of MMP expression by cytokines diverges.
Discussion
Active migration of cells and invasion of the tumor into
the surrounding normal brain tissue are key features of
glioblastomas [2,3]. It has been shown that MMP-9,
MMP-2 and its activator MMP-14 are involved in these
processes [37-40]. Therefore, these MMPs have been
extensively studied in several glioblastoma cell-lines
(Table 1 and references stated there) and first clinical
trials are performed for treatment of GBM patients by
inhibition of MMPs [41]. However, data about expres-
sion of other MMPs in these cells are limited (Table 1).
The only comprehensive study is an analysis of U251
cells by quantitative real time PCR for expression of all
known 23 human MMPs [31].
Since it has been reported that there are differences in
the expression patterns of MMPs in different cell-lines,
even if they originate from the same type of tissue [42],
we analysed 7 glioblastoma cell-lines (SNB-19, GaMG,
U251, U87, U373, U343 and U138) for expression of 15
MMPs (MMP-1, -8, -9, -10, -11, -13, -17, -19, -20, -21,
-23, -24, -26, -27, -28) by semiquantitative RT-PCR. For
expression of the remaining MMPs in most of the ana-
lyzed cell-lines there are already data available in the lit-
erature. These literature-data and our own results are
summarized in Table 1.
It is conspicuous that MMP-13, -17, -19 and -24 were
expressed by all analyzed cell-lines, whereas MMP-20
and MMP-21 were not expressed by any of the GBM
cells (Table 1, Figure 1, Figure 2). We also did not
detect any expression of MMP-8, -26 and -27 in any of
the cells examined, whereas Nuttall et al. reported
detection of mRNA of these MMPs in U251 cells by
quantitative real time PCR [31]. This discrepancy may
be due to a higher sensitivity of real time PCR in com-
parison to our semiquantitative approach. However, our
results for MMP-8 and MMP-26 in U251 cells match to
those obtained by other groups [26,27]. Chernov et al.
performed genome-wide transcripitional profiling and
quantitative reverse transcription-PCR of U251 cells
[26]. Whereas they found expression of MMP-2, -7, -10,
-13, -15, and -16, they did not detect MMP-8 expression
[26] and Deng et al. were choosing U251 cells for their
MMP-26 overexpression experiments, because these
cells did not originally display MMP-26 expression [27].
Controversial data about MMP expression have also
been reported for MMP-2 in U251, MMP-3 in U87,
U373 and U138, MMP-7 in U87 and U138, MMP-9 in
SNB-19, U251, U87 and U373, MMP-11 in U251,
MMP-12 in U251 and U138, MMP-14 and -15 in U87
and U373 and MMP-16 in U251 cells (Table 1). For
detection of these MMPs such diverse methods as semi-
quantitative RT-PCR [19,27,36], quantitative real time-
PCR [26,31,34], gelatin zymography [10,19,20,25,
29,30,32,33,36], Northern-blotting [10,15,20,29,32],
Western-blotting [10,20,29,30,32,34,36], 125I Western-
blotting after protein concentration [33] and RNase pro-
tection assay [28] have been used. This list implies that
different methods may come to dissimilar conclusions,
due to disparate sensitivities and due to comparing
mRNA expression with protein expression or protein
activity. However, in most cases these studies coincide
Figure 3 Expression analysis of MMPs in primary glioblastoma
cells by semiquantitative RT-PCR. Four different primary cell
cultures, derived from patients biopsies, were passaged ten times.
Total RNA was isolated from passage 1 (p1), passage 5 (p5) and
passage 10 (p10) and used for MMP specific semiquantitative RT-
PCR, as described in Figure 1.
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in their results, as can be seen in Table 1 for expression
of most MMPs in U251, U87 and U373 cells, suggesting
that divergent data may also be caused by other factors.
Indeed, we saw fluctuations in MMP-1, -9, -11, -17, -19
and MMP-24 mRNA expression with increasing pas-
sages in some GBM cell-lines (Figure 1; Figure 2).
MMPs are highly regulated on the transcriptional and
also the protein level [35,38,39] and variations in MMP
expression, dependent on the number of passages in cell
cultures, have been reported [43]. It was suggested that
these variations in MMP expression may be due to
in vitro selection processes or karyotype evolution where
the transcription of either the enzyme and/or its inhibitor
may be affected and thus lead to an imbalance in the
MMP-regulatory network [43]. However, alterations of
MMP expression may also depend on the cells environ-
ment. MMP-2, -9 and MMP-14 are differentially upregu-
lated by increasing cellular density [44]. MMP-14
expression also was enhanced if U87 cells were cultured
as neurospheres instead as monolayers [45]. Compared
Figure 4 Regulation of MMP mRNA expression by TNF-a and TGF-b1. a) U251 and U373 cells were successively adjusted to grow in
medium without FCS and stimulated with 10 ng/ml TNF-a and TGF-b1 for 48 h, respectively. Control cells were treated with PBS/BSA solution
instead. Total RNA was isolated from these cells and MMP expression strength analysed as explained in Figure 1. Shown is one representative
experiment out of six. b) Densitometric quantification of MMP mRNA regulation by TNF-a (light grey columns) and TGF-b1 (dark grey columns),
respectively, from the above experiment in arbitrary units. Each value was normalized to the respective GAPDH mRNA expression. Shown are the
means of six independent experiments. The standard errors of the mean (SE) are shown as error-bars. Asterisks indicate statistically significant
(two-tailed t-test, p ≤ 0.05) alterations compared to the untreated control (white columns).
Table 2 Primers and conditions used for semiquantitative RT-PCR screening
Gene Forward primer Reverse primer Tm (°C) Cycles cDNA fragment size (bp) Genomic DNA (bp)
MMP-1 5’-AAGGCCAGTATGCACAGCTT-3’ 5’-TGCTTGACCCTCAGAGACCT-3’ 57 32 480 1.060
MMP-8 5’-TCTGCAAGGTTATCCCAAGG-3’ 5’- ACCTGGCTCCATGAATTGTC-3’ 57 32 154 852
MMP-9 5’-CCTGCCAGTTTCCATTCATC-3’ 5’-GCCATTCACGTCGTCCTTAT-3’ 58 32 455 957
MMP-10 5’-CCAGTCTGCTCTGCCTATCC-3’ 5’- CATCTCAGATCCCGAAGGAA-3’ 55 32 819 4.199
MMP-11 5’-GGGGATGTCCACTTCGACTA-3’ 5’-CAGTGGGTAGCGAAAGGTGT-3’ 50 32 165 308
MMP-13 5’-AACATCCAAAAACGCCAGAC-3’ 5’-GGAAGTTCTGGCCAAAATGA-3’ 57 32 166 1.117
MMP-17 5’-GGAGCTGTCTAAGGCCATCA-3’ 5’-CGACAGGTTCCTCTTGTTCC-3’ 56 32 190 474
MMP-19 5’-CAGCCTCGTTGTGGCCTAGA-3’ 5’-ACCAGCCTGCACCTCTTGGA-3’ 55 32 207 430
MMP-20 5’-CGACAATGCTGAGAAGTGGA-3’ 5’-ATCTTTGGGGAGGTGGAATC-3’ 57 32 169 975
MMP-21 5’-GACGACGACGAGCACTTCAC-3’ 5’-TTTCCTGTCTGACCAGTCCA-3’ 53 32 180 431
MMP-23 5’-TGGGACCACTTCAACCTCAC-3’ 5’-CGTGTTGTGAGTGCATCAGG-3’ 55 32 412 938
MMP-24 5’-GAACCTGTGGGCAAGACCTA-3’ 5’-TGACAACCAGAAACTGAGCG-3’ 52 32 214 2.650
MMP-26 5’-GATATGAAGCCATCCGCAGT-3’ 5’-GCTGGAAGGTTCTAGGGTCG-3’ 58 32 378 1.470
MMP-27 5’-TTGTTTCTTGTGGCTGCTCA-3’ 5’-GCTAAGCCAAAGGAACCCAC-3’ 53 32 194 376
MMP-28 5’-CACCTCCACTCGATTCAGCG-3’ 5’-AAAGCGTTTCTTACGCCTCA-3’ 57 32 208 376
GAPDH 5’-GCAGGGGGGAGCCAAAAGGG-3’ 5’-TGCCAGCCCCAGCGTCAAAG-3’ 68 21 566 851
Tm: annealing temperature, bp: base pairs.
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to its expression in U251 cells growing in two-dimen-
sional matrix, MMP-12 expression increased during
growth in a three-dimensional Tenascin-C matrix [46].
U87 cells displayed low MMP-7 expression in culture,
which was much higher after implantation of the cells
within the brain of RAG 2/gc immune-deficient mice
[47], suggesting that the astrocyte environment may
influence MMP expression. Astrocytes in culture pro-
duce significant amounts of pro-MMP-2, but undetect-
able levels of active MMP-2. Co-cultured U251 cells are
then able to convert pro-MMP-2 into its active form
[48]. Therefore, we wondered if primary cells derived
from tumor biopsies from patients will change their
MMP expression pattern (Figure 3). We analysed tumor
samples of GBM-patients by semiquantitative RT-PCR
[16] (and unpublished results). From four of these tumors
we isolated and cultured primary cells and analysed them
at passage 1, passage 5 and passage 10 (Figure 3). Already
passage 1 showed a completely altered MMP expression
pattern as seen in the corresponding tumor tissue and
this pattern was not stable, but changed with further pas-
sages (Figure 3). The pattern was similar to the one seen
in established GBM cell-lines, although there were also
differences. MMP-1, -11, -17, -23 and MMP-24 expres-
sion was stronger in the primary cells. MMP-9 expres-
sion showed more alterations during passages in primary
cells, but was more stably expressed in the cell-lines.
MMP-13 and MMP-28 expression was nearly absent in
primary cells, whereas it clearly was visible in the cell-
lines (Figure 1).
Together these data indicate that there is a large variety
in the MMP expression patterns between different cell-
lines and primary cells and that these expression patterns
are changeable with duration of cell culture and are highly
dependent of cell culture conditions and cell-density.
Most importantly, these expression patterns do not match
to those seen in GBM tumor tissue of patients.
In vivo MMPs are regulated by the surrounding tissue
and by growth-factors or cytokines [35,38,39]. Glioblasto-
mas are highly hypoxic and hypoxia upregulates MMP-2
mRNA expression in U87, U251, U373 and LN18 glioblas-
toma cell-lines by activation of the HIF-1 transcription
factor, thereby enhancing their invasive potential [49].
Migration and invasion of U87 and T98G GBM cells is
also facilitated by NO, which can be found in high concen-
trations in glioblastoma tissue [50]. NO stimulates MMP-1
expression and activity [50]. Epidermal growth factor
(EGF) raises MMP-14 expression in U251 cells, but does
not influence MMP-15, -16 or MMP-24 [34]. MMP-2
expression and secretion is induced by IL-6 in U87 cells
[51]. However, IL-6 action seems to be cell-line specific,
since U343 cells were not affected [51]. We analysed
the effect of tumor necrosis factor-a (TNF-a) and trans-
forming growth factor-b1 (TGF-b1) on MMP-1, -9, -11,
-19 and MMP-24 expression in U251 and U373 cells
(Figure 4). TNF-a and TGF-b1 are inflammatory and
immunsuppressive cytokines, respectively. They have been
implicated in migration and invasion of glioma cells
in vitro [52-54]. However, it seems that they have converse
impact [52]. In U251 and in U373 cells TNF-a stimulated
expression of MMP-9 and MMP-19 (Figure 4). MMP-1
mRNA expression was significantly increased in U373
cells by this cytokine, whereas its expression in U251 cells
remained unaffected (Figure 4). This may be due to the
high basal level of MMP-1 expression displayed by U251
cells, which does not allow a further increase, or it may be
a cell-line specific effect. Such an effect has been observed
for MMP-1, -2, -3 and MMP-7 regulation by TNF-a and
TGF-b1, which caused marked induction of expression
only in some GBM cell-lines, but not in others [15]. TNF-
a enhances invasivenes of T98G cells through MMP-3
induction, but has no effect on MMP-1, -2 or MMP-9
expression [55]. However, in U251 cells TNF-a inhibits
MMP-2 expression and decreases invasiveness through an
extracellular matrix [56]. In A172 cells TNF-a induces
gene expression and protein secretion of MMP-9 [57].
TGF-b1 alone had no effect on MMP-9 production. How-
ever, when it was added together with TNF-a a significant
dose-dependent inhibition of MMP-9 secretion was
observed [57]. TGF-b1 displayed inconsistent effects on
adhesion and invasiveness, depending on the cell-line
examined. The invasive potential of U138 cells was mark-
edly reduced whereas U373 cell invasion remained
unchanged [58]. TGF-b1 caused significant induction of
MMP-11 and MMP-24 expression in U373 cells, whereas
we did not find any impact on MMP expression in U251
cells (Figure 4). In U87 and LN229 cells TGF-b1 upregu-
lates MMP-2 [53,54]. Thus, the transcriptional modulation
of MMP genes in response to TNF-a or TGF-b1 is not
consistent, but highly cell-line specific [15].
Conclusions
Data from literature and our own results suggest that
not only is the expression pattern of MMPs highly vari-
able, dependent on the cell-line and the culture-condi-
tions used, but also regulation of MMP expression by
cytokines diverges. This is of high impact, if results
from cell-culture experiments will be brought forward
to the situation in tumor tissue or even will be com-
muted to clinical applications.
Methods
Cell-lines and cell culture
Expression of MMPs was investigated in seven human
GBM cell-lines and in four GBM primary cell cultures,
which were prepared from GBM tissue samples of
patients as described previously [19]. SNB-19, U251,
U87, U373, U343 and U138 were originally purchased
Hagemann et al. BMC Research Notes 2010, 3:293
http://www.biomedcentral.com/1756-0500/3/293
Page 7 of 10
from ATCC (American Type Culture Collection, Rock-
ville, MD) [23]. GaMG cells were established from a
patient by the Gade Institute of the University Bergen,
Norway [59].
Primary cells and cell-lines were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) (CytoGen, Sinn,
Germany) supplemented with 10% fetal bovine serum
(FCS), 4× nonessential amino acids, 3 mM L-Glutamine,
Penicillin (100 U/ml) and Streptomycin (100 mg/ml) (all
from Invitrogen, Carlsbad, USA). Cells were grown as
monolayer in 75 cm2 flasks (Corning, New York, USA)
at 37°C in a humidified atmosphere containing 5% CO2.
Primary cells were grown from passage number 1 to 10
and cell-lines were passaged 15 times (starting passage
was determined as passage 0).
Stimulation of cells with TNF-a and TGF-b1
The FCS concentration in the culture medium of U251
and U373 cells was successively reduced from 10% via
5% and 2.5% to 0% to adjust the cells to grow in med-
ium without FCS. Once cells reached 70% confluency
human recombinant TNF-a (10 ng/ml) or TGF-b1
(10 ng/ml) (both from Sigma-Aldrich, St. Louis, USA)
was added for 48 h [60]. Control cells were treated with
PBS containing 2 mg/ml BSA.
RNA extraction and semiquantitative RT-PCR
Total RNA was isolated from the GBM cells using the
Nucleo-Spin RNA/Protein Kit (Macherey-Nagel, Düren,
Germany) following the manufacturer’s protocol. During
RNA extraction contaminating genomic DNA was
digested with the provided DNase I, as suggested by the
manufacturer. Total RNA was eluted in a maximum
volume of 60 μl RNase-free water and purified samples
stored at -80°C.
The mRNA expression level of MMPs was evaluated by
semiquantitative RT-PCR. Total RNA (1-5 μg) was
reverse-transcribed using the RevertAid H minus first
strand cDNA synthesis kit (Fermentas, Ontario, Canada)
and the provided oligo(dT)18 primer. First-strand cDNA
synthesis was carried out at 42°C for 60 min in a final
reaction volume of 20 μl and synthesized cDNA stored at
-20°C. The amount of cDNA was normalized to the
intensity of the PCR product of the ubiquitously
expressed gene glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) which was used as internal control [61].
Polymerase chain reactions were carried out on the Ther-
mocycler T3 (Biometra, Göttingen, Germany). All primer
sequences and PCR conditions are listed in Table 2.
Template DNA was mixed with 2.5 U Taq polymerase,
10× Buffer with 1.5 mM MgCl2 (Eppendorf, Hamburg,
Germany), 200 μM dNTPs (Fermentas, St. Leon Rot,
Germany), 0.4 μM of both, forward and reverse primers
(Table 2) and formamide (used optionally at a final
concentration of 4%) in a total reaction volume of 25 μl.
PCR was performed as follows: 5 min at 94°C; 21-32
cycles (Table 2) of 30 sec at 94°C, 30 sec at the optimised
annealing temperature (Table 2), 30 sec at 72°C; followed
by a termination step of 10 min at 72°C. PCR products
were separated on 1% agarose gels (Sigma-Aldrich, Stein-
heim, Germany) containing 0.07 μg/ml ethidium-bro-
mide (Roth, Karlsruhe, Germany).
Densitometric quantification and statistical analysis
The intensity of ethidium bromide fluorescence was
densitometrically analyzed using the BioDocAnalyze
software (Biometra, Göttingen, Germany). The DNA
bands were normalized to the respective fragment inten-
sity of the housekeeping gene GAPDH. Statistical analy-
sis was performed using Microsoft Office Excel 2003
(Microsoft Deutschland, Unterschleißheim, Germany).
Values were expressed as means ± standard error of the
mean (SE). Statistical significance was defined by two
tailed t-tests and p ≤ 0.05 was considered to be
significant.
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